The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period.
The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth.
Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio's Zynteglo in June 2019 for -thalassemia, indicates the shift in preferences of companies toward other untapped segments.
Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space.
Further key findings from the study suggest:
Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors
In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA
Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma
North America dominated the global gene therapy market in 2019 as the U.S. is the largest market for clinical trials related to gene therapy, since around 60% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in the U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America
Key market players include Bluebird Bio, Novartis, UniQure, Gilead Sciences, Spark Therapeutics, and Celgene Corporation
These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics' Luxturna for selling the product outside the U.S.'
Key Topics Covered
Chapter 1 Executive Summary
Chapter 2 Research Methodology
Chapter 3 Gene Therapy Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 188.8.131.52 Robust gene therapy pipeline 184.108.40.206 Introduction of technological advancements 220.127.116.11 Increasing investment from the companies and partnerships 18.104.22.168 Growing prevalence of target diseases and increased demand for innovative medicine 3.1.2 Market restraint analysis 22.214.171.124 Regulatory, scientific, and ethical challenges associated with gene therapy 126.96.36.199 High prices of gene therapy medicines 3.1.3 Opportunity analysis 188.8.131.52 Rising investment for adoptive T cell transfer approaches of disease treatment 184.108.40.206 Facility expansion for cell and gene therapies 220.127.116.11 Technological advancements in manufacturing vectors 3.1.4 Challenge Analysis 18.104.22.168 Production capacity challenges 22.214.171.124 Manufacturing challenges pertaining to large-scale production of vectors 3.1.5 Regulatory framework 3.2 Gene Therapy Market - SWOT Analysis, by Factor (Political & legal, economic and technological) 3.3 Industry Analysis - Porter's 3.4 Pricing Analysis 3.5 Pipeline Analysis